Press Releases

December 03, 2014 Aduro Biotech announces preclinical data presented at American Association for Cancer Research Tumor Immunology and Immunotherapy Conference

October 23, 2014 Aduro presents updated interim results from Phase 1b clinical trial in mesothelioma at International Mesothelioma Interest Group Conference

October 16, 2014 Aduro expands collaboration with Johnson & Johnson Innovation and Janssen for lung cancer immunotherapies

October 15, 2014 Aduro BioTech announces interim Phase 1B clinical data of CRS-207 for the treatment of mesothelioma accepted for oral presentation at the International Mesothelioma Interest Group conference

October 09, 2014 Aduro BioTech’s Chief Scientific Officer, Thomas W. Dubensky, Jr., Ph.D., a featured speaker on action of vaccine adjuvants at Keystone Symposia

September 22, 2014 Aduro BioTech named one of Fierce 15 leading biotech companies in 2014

July 21, 2014 Aduro receives breakthrough therapy designation from FDA for innovative pancreatic cancer combination immunotherapy

July 17, 2014 Aduro names industry veteran and academic leader, Gerald Chan, DSc to its board of directors

June 11, 2014 Aduro secures $55 million Series C financing

June 02, 2014 Aduro announces ASCO presentation of promising results from Phase 1b clinical trial of its novel immunotherapy for the treatment of mesothelioma

May 29, 2014 Aduro announces license agreement with Johnson & Johnson Innovation for novel immunotherapies for prostate cancer

May 05, 2014 Aduro BioTech announces initiation of a clinical trial of its novel immunotherapy in patients with brain cancer at Providence Cancer Center

February 10, 2014 Aduro BioTech announces initiation of Phase 2b ECLIPSE trial to evaluate treatment of patients with pancreatic cancer with the company’s innovative immunotherapies

January 14, 2014 Aduro announces Phase 2 clinical trial results demonstrating statistically significant survival benefit in pancreatic cancer patients treated with its novel immunotherapies